# US 2026/0098033 A1 · Novel crystalline form of enavogliflozin, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098033 A1
- Document ID: US20260098033A1
- Status: Published application
- Kind: A1
- Application number: 19/115,817
- Filed: 2023-09-27
- Published: 2026-04-09
- Earliest claimed: 2022-09-28
- Assignees: Daewoong Pharmaceutical Co., Ltd.
- Applicants: Daewoong Pharmaceutical Co., Ltd.
- Inventors: Youn Jung Yoon; Hee Kyoon Yoon; Ji Soo Choi; Hye Young Ji; Hyun Woo Lim
- Web page: https://patentgrep.com/patent/US20260098033A1

## CPC

- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/351: not condensed with another ring
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to a novel crystalline form of enavogliflozin, and a preparation method therefor. The novel crystalline form of enavogliflozin, according to the present invention, has thermodynamic stability and a hygroscopic property that are superior to those of a conventionally reported crystalline form of enavogliflozin, and thus has excellent long-term storage and pharmaceutical stability. In addition, the time to reach Cmax is shorter than that of the conventionally reported crystalline form of enavogliflozin such that drug effects can be rapidly exhibited, and thus the present invention can be effectively used.

## Claims

### Claim 1

A crystalline form of enavogliflozin, which is characterized by an X-ray powder diffraction pattern having four or more diffraction peaks at 2[θ] values selected from 4.93±0.2, 6.12±0.2, 7.43±0.2, 8.89±0.2, 9.74±0.2, 14.79±0.2, 15.79±0.2, 16.11±0.2, 19.79±0.2, and 22.83±0.2 in powder X-ray diffraction (PXRD) analysis.

### Claim 2 (depends on 1)

The crystalline form of claim 1, wherein the X-ray powder diffraction pattern has a diffraction peak at a 2[θ] value selected from 7.43±0.2, 14.79±0.2, 15.79±0.2, 16.11±0.2, and 19.79±0.2.

### Claim 3 (depends on 1)

The crystalline form of claim 1, which is characterized by an X-ray powder diffraction pattern with peak positions matching those listed in the following table:
2θ (±0.2°)
d (Å)
I/Io(%)
4.93
17.9
34.7
6.12
14.4
54.7
7.43
11.9
58.4
8.89
9.9
37.5
9.74
9.1
36.2
14.79
6.0
100.0
15.79
5.6
46.0
16.11
5.5
38.1
19.79
4.5
33.0
22.83
3.9
30.9
23.78
3.7
19.7

### Claim 4 (depends on 1)

The crystalline form of claim 1, which shows an endothermic peak with an endothermic onset temperature of 170.58° C.±3° C. and an endothermic peak temperature of 174.06° C.±3° C. in differential scanning calorimetry (DSC).

### Claim 5 (depends on 1)

A method of preparing the crystalline form of enavogliflozin of claim 1, comprising adding water to solid enavogliflozin, heating and stirring, and filtering and drying to obtain the crystalline form of enavogliflozin.

### Claim 6 (depends on 5)

The method of claim 5, wherein water is added in a volume 6 times or more the weight of solid enavogliflozin.

### Claim 7 (depends on 5)

The method of claim 5, wherein the heating is performed at 50° C. or more.

### Claim 8 (depends on 5)

The method of claim 5, wherein the stirring is performed for 8 hours or more.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the crystalline form of enavogliflozin of claim 1 as an active ingredient and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The composition of claim 9, which is used for treating or preventing diabetes.
